Why IsoRay (ISR) Stock Is Surging Today

NEW YORK (TheStreet) -- IsoRay  (ISR) surged Tuesday after the company announced the world's first liquid cesium-131 treatment for metastatic brain cancer.

IsoRay reported the treatment of a brain tumor that had metastasized from esophageal cancer with the company's liquid Cesium-131, also called Cesitrex, which recently received FDA clearance for internal radiation therapy. The treatment used GliaSite radiation therapy Balloon Catheter System, which delivers a high dose of radiation to an area and minimizes radiation exposure to healthy brain tissue.

The stock was up 10.12% to $2.94 at 10:36 a.m. on Tuesday.

Must Read: Warren Buffett's 25 Favorite Stocks

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

ISR Chart

ISR data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

More from Markets

Credit Suisse Surges After Strong Q1, Record Wealth Management Inflows

Credit Suisse Surges After Strong Q1, Record Wealth Management Inflows

Global Stocks Slide as Yield Pressure, Commodity Surge Prompts Equity Exit

Global Stocks Slide as Yield Pressure, Commodity Surge Prompts Equity Exit

Asian Markets Decline in Morning Trading

Asian Markets Decline in Morning Trading

Verizon Proves Resilient in Sell-Off; Decoding the Facebook Short -- ICYMI

Verizon Proves Resilient in Sell-Off; Decoding the Facebook Short -- ICYMI

Three Big Factors That Rocked the Stock Market Tuesday

Three Big Factors That Rocked the Stock Market Tuesday